Newsfeeds Archive - Page 37 of 56

2 minute read

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News

January 21, 3:52 PM

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

MSSTF

2 minute read

Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction

By Lara Goldstein

January 20, 7:37 PM

Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is set to commence this February.

FLHLF

2 minute read

Psychedelics Travel: Clinical-Grade Magic Mushrooms Extract Exported From Southern Africa To UK

By Lara Goldstein

January 20, 6:39 PM

Lifesciences psychedelics biotech Psyence Group Inc. (OTCQB: PSYGF) recently exported purified pharmaceutical-grade psilocybin mushroom extract from its licensed and certified production facility in Southern Africa to its Contract Development & Manufacturing Organization (CDMO) partner in the UK.

PSYGF

2 minute read

Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

By Lara Goldstein

January 20, 10:29 AM

(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights.

CMND

1 minute read

Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects

By Lara Goldstein

January 19, 3:57 PM

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

BSX

2 minute read

Psychedelics Market Could Reach $12B By 2029, Says New Report

By Lara Goldstein

January 19, 2:10 AM

A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before 2030.

CMPS

2 minute read

Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results

By Lara Goldstein

January 18, 6:43 PM

Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ:

IXHL

2 minute read

Cybin Touts Promising Results From Sponsored Kernel Flow Study Measuring Psychedelic Effects On The Brain

By Lara Goldstein

January 18, 3:34 PM

Cybin Inc.

CYBN

4 minute read

Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood’s Latest Moves And More

By Lara Goldstein

January 17, 7:38 PM

Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.

ATAI

2 minute read

Psychedelics Companies Join The Race To Develop Much-Needed Anxiety Treatment

By Lara Goldstein

January 16, 5:31 PM

Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004.

CYBN